At present, numerous experimental results indicate that EZH2 overexpression promotes proliferation, migration and invasion of cancer cells in endometrial cancer, lung cancer, melanoma, breast cancer, bladder cancer and colorectal cancer [31–33]. Here, EZH2 is linked to breast carcinoma.